Ruxolitinib (Jakafi)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Kinase inhibitor of Janus Associated Kinases (JAKs) JAK1 and JAK2. Modulates gene expression by interfering with the JAK signaling pathway, which involves recruitment, activation, and localization of STATs (signal transducers and activators of transcription) to cytokine receptors and the nucleus.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]

Diseases for which it is established

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2012-08-23: Initial authorization

History of changes in Health Canada indication

  • 2012-06-19: Initial notice of compliance

History of changes in PMDA indication

  • 2014-07-04: Initial approval for the treatment of myelofibrosis.
  • 2015-09-24: New additional indication and a new dosage for the treatment of polycythemia vera (use only when conventional therapies are not sufficiently effective or inappropriate).

Also known as

  • Code name: INCB-018424
  • Generic name: ruxolitinib phosphate
  • Brand names: Jakafi, Jakavi